The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico

Moye-Holz, Daniela; Dijk, Jitse P. van; Reijneveld, Sijmen A.; Hogerzeil, Hans V

doi:10.1016/j.vhri.2019.04.006

Cited by 18 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be the result of ineffective or lack of pricing regulations in these countries [25,65,66]. Colombia and Brazil control the prices of cancer medicines, while Peru and Chile have kept a free pricing system (i.e., no price regulation or control) [67,68], and Mexico has a mixed system of free pricing in the private sector and price control through price negotiations in the public sector [27,69]. As governments move on expanding health coverage, emerging markets with a large population size, like those in LATAM, could be considered attractive to the pharmaceutical industry [70,71].…”

Section: Prices Of Cancer Medicinesmentioning

confidence: 99%

Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America

Moye-Holz

Vogler

2021

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

Background There are concerns that high prices of cancer medicines may limit patient access. Since information on prices for cancer medicines and their impact on affordability is lacking for several countries, particularly for lower income countries, this study surveys prices of originator cancer medicines in Europe and Latin America and assesses their affordability. Methods For 19 cancer medicines, public procurement and ex-factory prices, as of 2017, were surveyed in five Latin American (LATAM) countries (Brazil, Chile, Colombia, Mexico, and Peru) and 11 European countries (Austria,

show abstract

Section: Prices Of Cancer Medicinesmentioning

confidence: 99%

Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America

Moye-Holz

Vogler

2021

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inability to afford healthcare and treatment can not only lead to treatment disparities between patients who can and cannot overcome the cost barriers (Wahlster et al 2015) but also make attempts to close the health disparity gaps challenging. Findings from this study are related to a recent study conducted in Mexico by Moye-Holz et al (2019) that finds improvement in healthcare access in the public sector after the establishment of a commission that negotiates pricing for patented medicine. To prevent delays in treatment seeking, attempts to improve healthcare affordability should focus on individuals assigned to both clusters, especially those assigned to the second cluster.…”

Section: Discussionmentioning

confidence: 75%

Healthcare satisfaction among the older adults with Alzheimer’s disease or dementia

Liew

2021

SN Soc Sci

View full text Add to dashboard Cite

The study seeks to examine how older adults in the United States with either Alzheimer's disease or dementia rate the importance of attributes associated with healthcare seeking and utilization (e.g., affordability, type of facility, and accessibility). Using conjoint and cluster analyses, the purpose of this study is assessed using data from the 2014 Health and Retirement Study. Findings revealed that satisfaction pertaining to these attributes slightly differed across clusters. This suggests that it is important to ensure that healthcare services are affordable and accessible, and the preferences of older adults are taken into consideration when making treatment or other relevant programmatic recommendations.

show abstract

“…After the expensive novel anticancer medicines were coverage by the social health insurance programmes, utilisation of the newly covered medicines in developed regions was higher than that in less developed regions, and medicines utilisation of patients enrolled in better health insurance programmes (with a better benefits package, like the programmes for the oil company staff, etc) was higher than that of those enrolled in a health insurance programme with weaker benefits package. 34 35 A study in the USA and other developed countries also showed that patients with different demographic, social and economic characteristics had disparities in adoption of novel anticancer medications. A cohort study of HER2-positive patients with breast cancer based on the Medicare data found that, within 1 year of being diagnosed, the proportion of the white patient treated with novel antibreast cancer medicines was significantly higher than that of the black.…”

Section: Discussionmentioning

confidence: 99%

Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design

Diao

Lin

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionLittle is known about the impact of the government’s efforts in having novel anticancer medicines covered by the public health insurance system in China. This study targeted the above policy implemented in Fujian province in 2017, analysed the policy impact on the medical expenditure of cancer treatment and patient affordability based on the clinical data of Fujian provincial medical centre.MethodsThe study included 253 human epidermal growth factor receptor 2-positive patients with breast cancer who completed at least one course of trastuzumab treatment extracted from the hospital health information system of the provincial medical centre of Fujian. We adopted the propensity score-matching method to mimic a quasi-experimental design to estimate the impact of the public health insurance coverage policy on all the indicated patients with a before–after comparison of the total breast cancer-associated direct medical expenditures for a standard course of treatment or maintenance treatment and the proportionate patient out-of-pocket (OOP) expenditure based on the real clinical data.ResultsWe found evidence of an association between the public health insurance coverage of novel breast cancer medication and the reductions of the medical expenditure by US$18661.02 (95% CI 13 836.57 to 28 201.45), and the proportionate patient OOP expenditure by 24% (95% CI0.20 to 0.27). The medical expenditure and the proportionate patient OOP expenditure might be generally reduced.ConclusionsThe coverage of innovative antibreast cancer medicines by the public health insurance was found to be associated with a reduction of the medical expenditure and share of patient OOP expenditure for cancer treatment of the indicated patients. Patients with lower ability-to-pay did not benefit well from the coverage policy. To maximise the welfare of the public health insurance coverage of novel anticancer medication, the study called for strengthened health insurance benefit packages of the rural patient and the patient enrolled in the urban and rural resident health insurance programme, who might have lower ability-to-pay and need more support from the public security system.

show abstract

The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico

Cited by 18 publications

References 33 publications

Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America

Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America

Healthcare satisfaction among the older adults with Alzheimer’s disease or dementia

Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design

Contact Info

Product

Resources

About